|Day's Range||64.92 - 65.20|
|52 Week Range||55.10 - 66.80|
|PE Ratio (TTM)||41.42|
|Dividend & Yield||1.88 (2.94%)|
|1y Target Est||N/A|
Cambridge cancer drug developer Enumeral could be forced to downsize, file for bankruptcy or sell its assets unless it quickly raises additional capital, the company said this week. Amid the cash crunch, Enumeral said it is “exploring a range of potential transactions.” According to the company, that could include a public or private offering, debt financing, collaborations and licensing deals, or a potential merger or asset sale. A representative for Enumeral did not immediately respond to an interview request on Friday.
UnitedHealth Group, Inc.???s (UNH) information and technology-enabled health services business "Optum" recently announced its collaboration with Merck & Co. Inc (MRK).
Merck & CO, Inc. (MRK) announced that it has bought exclusive worldwide license from Teijin Pharma for the development, manufacture and commercialization of an investigational preclinical anti-tau antibody.